Pluto Bioinformatics

GSE151317: Gene Expression Profiling of TNBC and OVCA in response to Azacitidine and Talazoparib (RNA-Seq)

Bulk RNA sequencing

Triple negative breast cancer and ovarian cancer cells were treated with Azacitidine, Talazoparib, or combination for a period of 10 days to assess global transcriptional response. The focus of these transcriptional studies were on the assessment of DNA repair and immune pathway alteration. SOURCE: Michael,Jonathan,Topper Johns Hopkins University